Jessica Kendrick, MD, MPH

New Capabilities

Presented the Phase 3 findings at ASN Kidney Week 2026

Nearly all dialysis patients develop secondary hyperparathyroidism, a condition where parathyroid hormone rises out of control and raises the risk of bone fractures and heart disease. On October 23, Pathalys Pharma reported that its intravenous drug upacicalcet cut parathyroid hormone by at least 30% in 42% of treated patients, against 17% on placebo, in two identical Phase 3 trials.

Updated Nov 2